Calamus

What is Calamus?

Calamus is the rhizome of Acorus calamus L., banned from US food since May 9, 1968 under 21 CFR 189.110. That regulation, published at 33 FR 6967 and codified in 1977 at 42 FR 14659, is the most important fact about the plant and the one least likely to appear on a bottle.

It is a wetland perennial in the family Acoraceae, and the confusion within the genus drives most of what follows. Acorus americanus Raf. is a fertile diploid at 2n = 24, native to the northern United States and Canada. Acorus calamus var. calamus is a sterile triploid at 2n = 36, spread across Europe and western Asia by vegetative propagation. Acorus calamus var. angustatus is a tetraploid from India and eastern Asia. Acorus tatarinowii Schott is a separate species used in Chinese medicine. These plants look nearly alike, sell under one English word, and differ in their key toxicological constituent by more than an order of magnitude.

Common Names

• Sweet flag, sweet sedge, flagroot, cinnamon sedge
• Bitterroot, muskrat root, rat root
• Sinkpe tawote, the Lakota name, translating roughly as muskrat food
• Vacha, the Ayurvedic drug name; Bach in Hindi; Vasambu in Tamil
• Shui Chang Pu in Chinese, distinct from Shi Chang Pu, which is Acorus tatarinowii
• Jammu oil of calamus, the trade name for the Indian tetraploid essential oil

Primary Active Compounds

• Beta-asarone (cis-2,4,5-trimethoxy-1-propenylbenzene), CAS 5273-86-9, EINECS 226-096-6, molecular weight 208.26, the compound that drives the regulatory picture
• Alpha-asarone, the trans isomer, in smaller and more variable amounts
• Total volatile oil, obtained from dried rhizome by steam distillation, at yields that vary widely by cytotype and origin
• Sesquiterpenes including shyobunone, acorenone and acorone, which dominate the oil of low-asarone chemotypes
• Acorin, the historical name for the bitter glycosidic fraction behind the gastric effect
• Dioxosarcoguaiacol and related sesquiterpenoids, positive allosteric modulators at GABA-A receptors
• Mucilage, starch, tannins and lectins in the whole rhizome

Key Note

The asarone fraction is a property of the cytotype, not the species. The European Medicines Agency’s Committee on Herbal Medicinal Products, in public statement EMEA/HMPC/139215/2005 adopted in November 2005, found beta-asarone not detectable in the diploid var. americanus, at 9 to 19 percent of rhizome essential oil in the triploid var. calamus, and 85 to 95 percent in the tetraploid var. angustatus. On the dried rhizome that is roughly 0.3 percent for the triploid and 4.4 to 8.3 percent for the tetraploid. The committee wrote that “diploid varieties should always be preferred.”

Everything downstream depends on which of the three plants went into the grinder.

Primary Functions & Benefits

Bitter gastric stimulant

Bitter compounds acting on lingual and gastric TAS2R receptors trigger a vagally mediated rise in gastric acid, pepsin and gastrin secretion. This is the oldest and best supported use and needs the smallest doses. A 1 cm piece of chewed root or 15 drops of a 1:2 tincture works in 5 to 15 minutes.

Carminative and antispasmodic

The volatile oil relaxes intestinal smooth muscle in isolated tissue, the mechanism behind traditional use for colic, flatulence and cramping. The effect is shared with most aromatic carminatives and not specific to asarone.

Central nervous system activity

Acorus calamus extracts contain positive allosteric modulators at the GABA-A receptor, structurally characterized by NMR and molecular modeling. Beta-asarone crosses the blood-brain barrier and produces sedative, anticonvulsant and anxiolytic effects in rodents at 5 to 100 mg/kg. Alpha- and beta-asarone make up about 95 percent of the volatile oil of Acorus tatarinowii, the species behind most Chinese neurological research.

Cholinergic effect

The essential oil inhibits acetylcholinesterase in vitro, the stated rationale for the cognition research. That does not establish a clinical effect at any oral dose in humans.

Traditional applications without trial data

Traditional systems used calamus for fever, cough, sore throat, toothache, epilepsy, memory, speech disorders and stammering in children. None of these human claims has been tested in a controlled trial.

Forms & Standardization

Form determines the beta-asarone dose by two orders of magnitude.

Whole dried rhizome, cut and sifted

The most common retail form, sold by weight in 4 oz to 1 lb quantities. Beta-asarone depends entirely on cytotype: essentially 0 percent for true Acorus americanus, around 0.3 percent for European triploid, 4.4 to 8.3 percent for Indian tetraploid. A 1 g dose of tetraploid rhizome delivers 44 to 83 mg; the same dose of American diploid delivers none. The label almost never says which.

Powder

Ground rhizome in 50 g to 454 g packs. Banyan Botanicals sells calamus powder from India and labels it “For external use only. Not for human consumption,” the honest response to 21 CFR 189.110 when your raw material is tetraploid. Powder oxidizes faster than cut root; expect real loss of aromatic character within 6 to 12 months.

Tinctures

Typically fresh rhizome at 1:2 by input weight, or dried at 1:5, in ethanol and water. Heron Botanicals sells a fresh calamus rhizome tincture at 1:2 with alcohol, water and vegetable glycerin, dosed at 0.5 to 1 mL (15 to 30 drops) two to three times per day. It declares no variety, no ploidy, no alcohol percentage and no beta-asarone figure. The upper dose is 3 mL daily, roughly 1.5 g of fresh rhizome.

Glycerites

Alcohol-free extracts commonly labeled at 700 mg per serving. Glycerin is a poor solvent for volatile oil relative to ethanol, so a glycerite of the same input ratio delivers less asarone and less aromatic activity.

Essential oil

Steam distilled from rhizome, at yields that vary widely by cytotype and origin. Indian-origin material, the trade product called Jammu oil of calamus, is the highest-asarone item on the market at 85 to 95 percent beta-asarone. This is the form used in the rat carcinogenicity study and should not be taken internally in any amount.

Chinese medicine material

Shi Chang Pu is Acorus tatarinowii Schott, not Acorus calamus. The Chinese Pharmacopoeia specifies volatile oil of not less than 1.0 percent (mL/g), with alpha- and beta-asarone making up about 95 percent of that oil. Published decoction doses cluster around 3 to 10 g. Shui Chang Pu is Acorus calamus, treated as a lower-grade substitute.

What standardization actually exists

Essentially none in US retail. There is no USP monograph for calamus, no adopted percentage standardization, no marker assay on labels and no required cytotype declaration. The only quantitative anchors sit outside the supplement industry: FDA’s incorporated analytical method at Journal of the AOAC volume 56, number 5, pages 1281 to 1283, September 1973; the EU limit of 1.0 mg/kg beta-asarone in alcoholic beverages, the only maximum level Regulation (EC) No 1334/2008 sets for the compound; and the EMA/HMPC temporary ceiling of about 115 µg/day, or 2 µg/kg body weight per day.

Put the EMA figure against product reality. At 4.4 percent beta-asarone, the 115 µg ceiling is reached at about 2.6 mg of powder. A 500 mg capsule of that material exceeds it by roughly 190-fold.

Food Sources

There are no dietary sources of calamus in the United States, by regulation rather than scarcity.

The prohibition

21 CFR 189.110 defines calamus as “the dried rhizome of Acorus calamus L.” and states that food containing any added calamus, oil of calamus, or extract of calamus is deemed adulterated. The threshold is any added amount: no tolerance, no action level, no de minimis exemption. The regulation carries a reference method for detecting oil of calamus as beta-asarone from the Journal of the Association of Official Analytical Chemists, volume 56, number 5, pages 1281 to 1283, September 1973, with amendments at 47 FR 11855 (March 19, 1982), 54 FR 24899 (June 12, 1989) and 78 FR 14667 (March 7, 2013).

What it was used in before 1968

Calamus was a standard flavoring in European and American bitters, vermouths, absinthes and liqueurs. Danziger Goldwasser and a range of stomachic bitters carried it, and candied calamus rhizome was sold as a confection in Europe into the 20th century. Manufacturers reformulated after 1968, one reason mid-century commercial bitters taste different from their 19th-century recipes.

Canada

Health Canada lists “Oil, extract or root of calamus from Acorus calamus L.” as forbidden in all foods on its List of Contaminants and Other Adulterating Substances in Foods. On November 4, 2016, Gourmet Nutrition F.B. Inc. recalled Phytovie Acore Vrai Calamus herbal tea after testing found excessive beta-asarone, with Health Canada warning that high intake “can lead to nausea, prolonged vomiting (for several hours), and a faster-than-normal heart rate.”

European Union

The EU regulated the compound rather than banning the plant. Beta-asarone as such may not be added to food, under Annex III Part A of Regulation (EC) No 1334/2008. Carried in from flavoring preparations, it is capped at 1.0 mg/kg in alcoholic beverages, which is the only maximum level Annex III Part B sets for the compound. The repealed Directive 88/388/EEC had also capped it at 0.1 mg/kg in foods and beverages generally and 1 mg/kg in snack seasonings, but those general limits did not carry over into the current regulation. A European bitter can legally carry trace calamus flavor; an American one cannot carry any.

Scientific Committee on Food and JECFA

The SCF opinion on asarone, SCF/CS/FLAV/FLAVOUR/9 ADD1 Final, adopted December 12, 2001, concluded that “the existence of a threshold cannot be assumed and the Committee could not establish a safe exposure limit.” That is the formal basis for treating beta-asarone as a genotoxic carcinogen with no safe intake. The Joint FAO/WHO Expert Committee on Food Additives reviewed beta-asarone in WHO Food Additives Series 16 and allocated no acceptable daily intake.

Fragrance

IFRA holds that cis- and trans-asarone should not be used as fragrance ingredients, and that essential oils containing them, calamus oil included, should not push total cis- plus trans-asarone above 0.01 percent in a finished consumer product.

Incidental exposure

Measurable beta-asarone still reaches consumers through herbal teas, imported bitters and Ayurvedic preparations. A 300 mL cup of calamus tea used in a controlled human metabolism study contained 0.76 mg beta-asarone plus 2.03 mg of asarone diols, roughly 6.6 times the EMA daily ceiling.

Who Should Take Calamus

The honest population is small.

People using it as a chewed aromatic bitter

Adults with sluggish digestion or low appetite who have sourced verified Acorus americanus. A 1 to 2 cm piece chewed before a meal is the traditional preparation and the lowest-exposure route.

People using it topically or as incense

External use carries no ingestion risk and is what most reputable US suppliers of Indian material now recommend.

Singers, speakers and people with motion sickness

Traditional North American use for hoarseness, throat irritation and travel nausea is well documented and dose-light, typically under a gram of root.

Practitioners of Ayurveda and TCM

Vacha and Shi Chang Pu are prescribed within diagnostic frameworks, in compound formulas, for defined courses. Shi Chang Pu is Acorus tatarinowii, commonly around 3 to 10 g per decoction, not Acorus calamus.

Who this is not for

Anyone wanting a daily supplement, a nootropic taken for months, or a capsule of Indian-origin powder.

Who Should AVOID or Use Caution

Contraindications

• Pregnancy and lactation. Beta-asarone is genotoxic in vitro with metabolic activation and no safe exposure level is established.
• Infants and children. Administration of vasambu, the Tamil preparation of Indian calamus, is documented in the pediatric literature as a harmful infant rearing practice.
• Anyone with a personal or family history of gastrointestinal cancer, given that the carcinogenic endpoint in rats was intestinal leiomyosarcoma.
• Anyone with active liver disease, since beta-asarone is metabolized hepatically through an epoxide intermediate.
• Internal use of calamus essential oil by anyone, at any dose, by any route.
• People with epilepsy on anticonvulsant medication, because of unquantified interaction risk.

Use Caution

• Anyone with reflux or active peptic ulcer disease, because the bitter action increases gastric acid secretion.
• Anyone on sedatives, benzodiazepines or alcohol, given GABA-A modulation by constituent sesquiterpenes.
• People scheduled for surgery within 2 weeks, on general principles for CNS-active botanicals.
• Anyone using Indian-origin material, which should be assumed tetraploid at 4.4 to 8.3 percent beta-asarone unless a certificate of analysis says otherwise.
• Anyone taking more than a gram of dried root per day for more than a few days.

Critical Safety Point

The Swedish Poisons Information Centre logged 30 inquiries about calamus between 2003 and 2006. Björnstad, Helander, Hultén and Beck published the analytical follow-up in the Journal of Analytical Toxicology in 2009, volume 33, issue 9, pages 604 to 609, covering 7 clinical cases. The dominant symptom was prolonged vomiting, sometimes lasting more than 15 hours. Urinary alpha-asarone ranged from 11 to 1150 µg/L across 5 positive samples and beta-asarone from 22 to 220 µg/L across 4. The study found no 2,4,5-trimethoxyamphetamine in any sample, disposing of the claim that calamus is metabolized into a hallucinogenic amphetamine. What it does at high dose is make people vomit for most of a day.

Recommended Dosages

Every figure below comes from traditional practice or vendor labeling. None has been established in a controlled human trial, and all exceed the EMA/HMPC ceiling of 115 µg beta-asarone per day if the material is triploid or tetraploid.

Chewed fresh or dried rhizome

A piece 1 to 2 cm long, roughly 0.3 to 1 g, chewed and the fiber discarded. Verified diploid delivers no beta-asarone; triploid at 0.3 percent delivers about 3 mg per gram, roughly 26 times the EMA ceiling.

Dried rhizome powder

Ayurvedic dosing for Vacha churna is commonly given as 125 to 500 mg once or twice daily, within a compound formula. At Indian tetraploid material at 4.4 percent, 250 mg delivers 11 mg of beta-asarone, roughly 96 times the EMA ceiling.

Tincture, fresh 1:2

0.5 to 1 mL, 15 to 30 drops, two to three times daily, per Heron Botanicals labeling. Daily maximum 3 mL.

Tincture, dried 1:5

1 to 2 mL up to three times daily, equivalent to 0.2 to 0.4 g of dried root per dose.

Infusion or decoction

1 to 3 g of cut root per 250 mL of water. A 300 mL calamus tea in a published human study contained 0.76 mg of beta-asarone.

Chinese medicine, Acorus tatarinowii

Commonly cited at 3 to 10 g per day in decoction, in formula, prescribed by a practitioner.

Essential oil

No internal dose exists. External only, and IFRA caps total asarone at 0.01 percent in finished consumer products.

Duration

Traditional use is acute and short. Bitter use is per-meal, and Ayurvedic courses run days to weeks within a formula. No traditional system uses calamus as a continuous daily supplement for months, and the rodent carcinogenicity data are a clear reason not to invent that pattern. Keep any triploid or tetraploid material under 2 weeks.

Timing & Administration

For digestive effect

Take 10 to 15 minutes before a meal. The bitter reflex requires oral contact, so hold tinctures in the mouth briefly; capsules defeat the purpose. Chewed root works fastest.

For nausea or motion sickness

Chew roughly 0.5 g at symptom onset or 20 to 30 minutes before travel.

For throat and voice

Chewed as needed. Traditional accounts describe under 2.5 cm of root total over an entire weekend of singing.

With food or without

Bitters work better on an empty stomach. Taking calamus with food blunts the gastric secretory response, the opposite of the intended effect. No circadian consideration is established, and where the sedative properties matter, evening dosing is the reasonable default.

Route

Oral for digestive use, topical for external. Inhaling the essential oil avoids the carcinogenicity question but not sensitization; the rhizome oil is classified a GHS Category 1B skin sensitizer and Category 2 irritant in OECD-compliant in vitro assessment.

Timeline of Effects

Calamus has an unusually well characterized human pharmacokinetic profile for a plant nobody studies clinically, because researchers used it as a model for asarone metabolism.

Seconds to 2 minutes

Bitter taste registers on contact with lingual TAS2R receptors, with the warming aromatic sensation following within about 30 seconds. This is the fastest observable effect and requires no absorption.

5 to 15 minutes

Vagally mediated increase in gastric secretion, appetite stimulation and reduced fullness. This is the entire useful window for the traditional digestive application.

15 to 45 minutes

Carminative and antispasmodic effects on the small intestine. Relief of cramping and flatulence, overlapping with initial absorption of volatile constituents.

1 to 6 hours

Peak urinary excretion of asarone metabolites in humans. Hermes, Römermann, Cramer and Esselen published this in Foods in 2021, volume 10, issue 9, in 10 healthy participants, 5 female and 5 male, mean age 25.8 ± 4.0 years and mean BMI 23.8 ± 1.9, given 300 mL of calamus tea containing 0.76 mg beta-asarone, 0.65 mg erythro-asarone diols and 1.38 mg threo-asarone diols.

Approximately 4.8 hours

Time to peak plasma concentration for beta-asarone after oral dosing in rats given Acori Tatarinowii Rhizoma at 2.16 g/kg, with Tmax 4.778 ± 3.777 h and Cmax 49.752 ± 16.049 ng/mL. Absorption is slow. Alpha-asarone peaks earlier at 3.542 ± 3.736 h and higher at 73.456 ± 25.933 ng/mL.

Approximately 10.7 hours

Terminal plasma half-life of beta-asarone by the oral route in the same rat model, at 10.662 ± 6.942 h. By intravenous administration the half-life collapses to about 13 minutes, which tells you the long oral half-life reflects slow absorption rather than slow clearance.

48 hours

Total urinary recovery in humans reached 42 ± 6 percent of administered asarone-derived material, excreted predominantly as erythro- and threo-asarone diol glucuronides. O-demethylated glucuronides and unconjugated diols made up the remainder. Sulfation was not observed in humans, which differs from some in vitro systems.

Up to 15 hours (overdose)

Duration of vomiting in the Swedish poisoning cases, the outer bound of an acute overdose episode.

2 to 12 weeks

The intervention window in the rodent Alzheimer’s model literature. Du and colleagues published a systematic review and meta-analysis in Frontiers in Pharmacology in 2022, volume 13, article 956746, pooling 12 studies at beta-asarone doses of 5 to 100 mg/kg/day, mostly intragastric.

84 weeks

The point past which no rat survived at 2000 ppm beta-asarone or 2500 ppm Jammu oil of calamus. The highest Jammu oil group, at 5000 ppm, died sooner still.

2 years

Full duration of the rat bioassay that produced the leiomyosarcomas and the 1968 ban.

What has no timeline

Cognitive benefit, anxiolysis, anticonvulsant effect and neuroprotection in humans. No controlled trial has established an onset time for any of these, because none has established them at all.

Benefits of Taking Calamus

Appetite and digestion

The strongest claim. Bitter stimulation of gastric secretion is a reproducible physiological effect and calamus is a potent example, effective at doses under 1 g.

Throat and voice

Chewed root reduces hoarseness and throat irritation, documented across Lakota, Dakota, Cree and other North American traditions.

Cognitive effects in rodents

A meta-analysis of 12 rodent studies found beta-asarone reduced Morris water maze escape latency by a weighted mean 12.61 seconds (95% CI 18.66 to 6.57) and increased platform crossings by 1.50 (95% CI 0.31 to 2.70). SYRCLE assessment rated the studies medium to high quality, and the authors’ own test for publication bias was not significant. A real animal effect and no human effect.

Insecticidal

Calamus oil is a well replicated insecticide and insect growth regulator, arguably its most defensible commercial application, and it does not involve eating it.

Anti-inflammatory and metabolic effects

Rodent data exist for rheumatoid arthritis, dyslipidemia and oxidative stress. All preclinical.

Potential Negatives & Side Effects

Common at ordinary doses

• Intense bitterness, unpleasant to many users, with increased salivation
• Numbing or tingling of the tongue and mouth from the volatile oil
• Mild nausea, particularly from powder in water on an empty stomach
• Increased gastric acid and reflux symptoms in susceptible people

Common at larger doses

• Vomiting, the most consistently reported adverse effect and the mechanism behind traditional emetic use
• Prolonged vomiting up to 15 hours in serious cases
• Tachycardia, flagged specifically by Health Canada
• Sedation and drowsiness

Topical

Calamus rhizome oil was classified a GHS Category 1B skin sensitizer and Category 2 irritant using OECD-compliant new approach methods. Sensitization is durable rather than transient, so repeated topical use carries real risk.

The long-term concern

Intestinal leiomyosarcoma in rats. It will not announce itself, and it is the reason the regulatory position is what it is.

Deficiency Symptoms

Calamus is not an essential nutrient, so no deficiency state exists and no intake level is required.

What calamus addresses

• Functionally low gastric secretion presenting as postprandial fullness, bloating and poor appetite
• Intestinal spasm and gas
• Throat irritation and hoarseness

None of these are deficiencies of calamus. They are conditions a bitter aromatic can influence, and gentian, artichoke leaf, wormwood and dandelion root all stimulate gastric secretion without being banned from food.

Bottom line

There is no physiological requirement for calamus, no reference intake, no biomarker of status, and no syndrome that develops in its absence.

Toxicity Symptoms

At high intake

• Prolonged vomiting, up to and beyond 15 hours, with persistent nausea
• Tachycardia, potentially serious
• Sedation, drowsiness, ataxia
• Abdominal pain
• Hypotension at very high doses in animal models

The acute oral LD50 for beta-asarone in rats is 1010 mg/kg, the intraperitoneal LD50 in mice 184.2 ± 1.0 mg/kg, and the LD50 for Acorus tatarinowii volatile oil in mice 0.22 ± 0.055 mL/kg. Scaled naively, the rat oral figure corresponds to about 70 g of pure beta-asarone for a 70 kg adult, not reachable from rhizome. The realistic acute hazard is the essential oil, where a few milliliters is a plausible exposure carrying a large asarone load.

Signs to reduce or stop

• Any vomiting
• Rapid or irregular heartbeat
• Persistent drowsiness
• Worsening reflux or epigastric pain
• Any skin reaction to topical preparations, which may indicate sensitization rather than irritation

General note

The chronic hazard is what regulators acted on. Taylor and colleagues dosed rats for 2 years, 25 per sex per group. In the Jammu oil of calamus arm, dietary levels of 500, 1000, 2500 and 5000 ppm corresponded to roughly 25, 50, 125 and 250 mg/kg body weight per day, and intestinal leiomyosarcomas appeared at 3/25 in females at 500 ppm and 5/25 and 2/25 in males at 1000 and 2500 ppm, with zero in controls. In the purified beta-asarone arm, in Osborne-Mendel rats at 0, 400, 800 and 2000 ppm, male leiomyosarcoma counts were 1, 6 and 9. The dose response is not clean, partly because no animal at 2000 ppm beta-asarone or 2500 ppm Jammu oil survived past 84 weeks. Beta-asarone was negative in the Ames test at 50 ppm and positive at 5000 ppm with metabolic activation.

How Calamus Works

Bitter receptor pathway

Bitter glycosides and sesquiterpenes activate TAS2R receptors on the tongue and in the gastric mucosa, triggering a vagal efferent response that raises gastric acid, pepsin and gastrin output and increases motility. The effect is reflexive and requires oral exposure, which is why capsules underperform.

GABA-A modulation and cholinesterase inhibition

Sesquiterpenoids isolated from Acorus calamus, including dioxosarcoguaiacol, act as positive allosteric modulators at GABA-A receptors, the plausible mechanism for sedative and anticonvulsant effects and distinct from the asarone pathway. The essential oil and its asarone constituents separately inhibit acetylcholinesterase in vitro, which does not establish a central cholinergic effect at oral doses achievable from rhizome.

Beta-asarone metabolism and the carcinogenic pathway

Beta-asarone is a propenylbenzene, structurally related to safrole, estragole and methyleugenol, which share the same toxicological problem. Hepatic cytochrome P450 enzymes epoxidize the propenyl side chain, generating a reactive epoxide that is the presumed DNA-reactive species. It is rapidly hydrolyzed to erythro- and threo-asarone diols, then glucuronidated by UDP-glucuronosyltransferases and excreted. In the 10-subject human study, glucuronidation dominated and sulfation was not detected. Detoxification is efficient but not complete, which is why regulators do not assume a threshold below which no risk exists.

Synergistic Supplements

Other bitters

Gentian root, wormwood, dandelion root and artichoke leaf produce the same gastric secretory effect. Combining them allows a much smaller calamus fraction for the same result.

Carminative aromatics

Fennel, ginger, cardamom and peppermint pair with calamus in traditional digestive formulas, reinforcing the antispasmodic effect.

Ayurvedic pairings

Vacha is classically combined with Brahmi (Bacopa monnieri), Shankhpushpi and Jatamansi in preparations aimed at cognition and speech, as a minor constituent at 125 to 500 mg within a larger compound.

Chinese formula context

Acorus tatarinowii appears in Kaixin San alongside Polygala, Poria and Ginseng. Rodent work used 0.9 to 2.7 g/kg/day for depression models and 3 to 10 g/kg/day for neuroinflammation models. It is never used alone.

What does not synergize

No co-supplement makes tetraploid calamus safe to take chronically, and claims otherwise are marketing.

Interactions & What NOT to Take

CNS depressants

Benzodiazepines, barbiturates, z-drugs, alcohol, opioids and sedating antihistamines. GABA-A modulation may compound sedation, and no human interaction study exists.

Anticonvulsants

Beta-asarone has reported anticonvulsant activity in rodent seizure models. Interaction with phenytoin, valproate or carbamazepine is unstudied and unpredictable. Avoid.

Acid-suppressing drugs

Proton pump inhibitors and H2 blockers work against the primary mechanism of calamus as a gastric secretagogue. Taking both is self-defeating.

Hepatically cleared drugs

Beta-asarone is a CYP substrate and undergoes extensive glucuronidation. Competition for UGT capacity is plausible and unquantified.

Anticoagulants

The EMA public statement cites anticoagulant activity among reported effects of asarone preparations. Combining with warfarin, apixaban or antiplatelet agents needs monitoring.

Other propenylbenzene botanicals

Sassafras (safrole), basil and tarragon oils (estragole), and nutmeg (myristicin, methyleugenol) share the same epoxidation pathway. Stacking them compounds exposure to related genotoxic carcinogens with no benefit.

What not to take, period

Calamus essential oil internally. Indian tetraploid powder in daily capsules. Any calamus product during pregnancy, lactation, or by a child.

Quality, Testing & Adulteration

This is where the category fails most completely, and the failures are specific.

Cytotype is not declared and is not testable by the consumer

The most decision-relevant property of calamus material is its ploidy, and it cannot be determined from dried root by eye, by smell, or by any test a retail buyer can run. Flow cytometry, chromosome counting or a molecular method will do it, and a published PCR-RFLP approach using an EcoRI restriction site distinguishes beta-asarone-free Acorus cytotypes precisely. No US retailer runs it routinely and no label reports it.

Beta-asarone assay exists and is not used at retail

Methods are mature. FDA’s own regulation incorporates an AOAC method from 1973, and micellar electrokinetic capillary chromatography, GC-MS, TLC and HPLC-MS/MS methods for asarone isomers are published and validated. A GC-MS run costs a fraction of the retail margin on a pound of root. It is almost never run, and when it is, the number does not reach the label.

Species substitution is documented

Lam and colleagues published an authentication study in Chinese Medicine in 2016 covering 16 market samples, 4 batches each of Acori Tatarinowii Rhizoma and three substituted materials: Acori Graminei Rhizoma, Acori Calami Rhizoma and Anemones Altaicae Rhizoma, from Hong Kong and mainland China. Neither morphological inspection nor UHPLC separated all four; ITS sequencing, producing amplicons of about 850 base pairs with interspecific distances of 0.572 to 0.605, did. Chemical fingerprinting alone did not catch the substitution.

Botanical origin substitutes

Iris germanica rhizome, Acorus gramineus and generic aromatic rhizomes have been reported as calamus substitutes in the wider herbal trade. Powder is the highest-risk form, because morphological identification is impossible once material is ground.

Geographic origin as a proxy

Origin is a weak but usable signal when ploidy is undeclared. Indian material should be assumed tetraploid at 4.4 to 8.3 percent beta-asarone in the dried root, European material from Poland, Hungary or the Balkans triploid at about 0.3 percent. Only wild-harvested North American material from verified Acorus americanus can be assumed asarone-free, and a label reading “American calamus” is not sufficient evidence of it. Mountain Rose Herbs states Poland. Banyan Botanicals states India. Both disclosures stop well short of ploidy.

Morphological authentication for whole material

Acorus americanus leaves carry 2 to 6 roughly equal prominent veins with smooth margins, and the plant sets small green berries. Acorus calamus has a single prominent midvein, undulate leaf margins, and being a sterile triploid, sets no fruit. Checkable on whole plants and useless on cut root.

What a lot-level document should carry

• Botanical name to variety, with authority: Acorus americanus Raf., or Acorus calamus L. var. calamus, or var. angustatus
• Ploidy, with method stated (flow cytometry, chromosome count or PCR-RFLP)
• Beta-asarone percentage by GC-MS or HPLC-MS/MS on the finished material, with LOQ stated
• Country and region of origin
• Volatile oil content by hydrodistillation
• Identity confirmation by ITS or matK sequencing for powdered material
• Heavy metals, pesticide residues and microbial limits

What you will actually find

A botanical name with no variety, a country of origin if you are lucky, an FDA disclaimer, nothing else. Of the products surveyed for this issue, none declared beta-asarone content or ploidy.

Special Considerations

Pregnancy, lactation and children

Avoid entirely. Beta-asarone is a genotoxic carcinogen with no established threshold, and vasambu administration is documented in the pediatric literature as a harmful infant rearing practice in South India, where Indian tetraploid calamus is traditionally given to infants.

Older adults

The cognition claims are aimed squarely at this group and rest on rodent data only. Reduced hepatic clearance is a further reason for caution.

Liver and kidney impairment

Metabolism proceeds through hepatic epoxidation and glucuronidation, so impairment shifts the balance toward the reactive intermediate. 42 ± 6 percent of an oral dose is recovered in urine within 48 hours, and reduced renal clearance prolongs exposure.

Legal status for sellers

21 CFR 189.110 addresses food, and dietary supplements are a subcategory of food under the Federal Food, Drug, and Cosmetic Act. Calamus products continue to sell in the US as supplements and as “not for internal use” botanicals, with FDA enforcement sparse rather than absent. Sellers who label Indian-origin material for external use only are reading the regulation the way it is written.

Wild harvesting and conservation

Acorus americanus is listed as endangered in Pennsylvania. Wild populations of the diploid are limited and pressured by the very demand its safety profile creates, so cultivated sources are preferable.

Heavy metals

Acorus is used in constructed wetlands for phytoremediation because it takes up metals efficiently from sediment, a direct reason to require heavy metal testing on rhizome for ingestion.

Hallucinogen claims

Calamus does not produce 2,4,5-trimethoxyamphetamine in vivo. The 2009 Swedish analytical study found none in any of the 7 case samples.

Research Status & Evidence Quality

Strong Evidence For

• Beta-asarone content varies by cytotype, from not detectable in the diploid to 85 to 95 percent of rhizome oil in the tetraploid. Tabulated by EMA/HMPC in 2005 and by SCF in 2001.
• Beta-asarone is carcinogenic in rats, producing intestinal leiomyosarcoma in a 2-year Osborne-Mendel bioassay with 25 animals per sex per group.
• Human metabolism proceeds through epoxidation to asarone diols then glucuronidation, with 42 ± 6 percent urinary recovery in 48 hours in 10 subjects.
• Calamus oil is an effective insecticide and insect growth regulator.
• High doses cause prolonged vomiting, documented in 7 analytically confirmed Swedish cases.

Moderate Evidence For

• Bitter aromatic stimulation of gastric secretion and appetite, mechanistically established for the bitter class.
• Antispasmodic activity on intestinal smooth muscle in isolated tissue.
• Positive allosteric modulation at GABA-A receptors by isolated Acorus sesquiterpenoids, with full structural characterization.
• Acetylcholinesterase inhibition in vitro by the essential oil and its asarone constituents.
• Skin sensitization by the rhizome oil, classified GHS Category 1B by OECD-compliant in vitro methods.

Emerging / Preliminary Evidence For

• Cognitive benefit in rodent Alzheimer’s models. Meta-analysis of 12 studies, beta-asarone 5 to 100 mg/kg/day for 2 to 12 weeks, escape latency reduced by a weighted mean 12.61 seconds. The authors’ test for publication bias was not significant.
• Anticonvulsant activity in rodent seizure models.
• Antidepressant effects, largely via Kaixin San formula studies at 0.9 to 2.7 g/kg/day in rats.
• Antimetastatic activity against MDA-MB-231 breast cancer cells, and cardioprotection by Acorus tatarinowii volatile oil at 100 to 160 mg/L in cardiomyocytes, both in vitro.

Research Limitations

There are no published randomized controlled trials of calamus for any indication in humans. The one recent human clinical publication is a multi-center open-label homeopathic verification study, not a controlled test at material doses. Most neurological research uses Acorus tatarinowii, a different species, and gets cited as though it applies to Acorus calamus. Most studies do not report cytotype, so a reader cannot tell which plant was tested. Rodent doses run 5 to 100 mg/kg/day of isolated beta-asarone, which for a 70 kg human scales to 350 to 7000 mg daily, far above what any rhizome preparation delivers.

Summary & Key Takeaways

Calamus is an effective bitter aromatic with a long history across Ayurvedic, Chinese, European and North American practice, and a regulatory problem that has nothing to do with whether it works. One constituent, beta-asarone, is a propenylbenzene carcinogen in the same structural family as safrole, and its concentration varies by more than an order of magnitude with the chromosome complement of the source population. The North American diploid has none. The Indian tetraploid rhizome is 4.4 to 8.3 percent beta-asarone by weight. FDA banned all of it from food in 1968 rather than attempt the distinction, and 58 years later almost no US supplement label makes the distinction either.

If you want a digestive bitter, gentian, wormwood, artichoke leaf and dandelion do the same job and are not prohibited food additives. If you want calamus specifically, the only defensible version is verified Acorus americanus from a supplier who documents ploidy.

Bottom Line

The plant is illegal to add to US food, capped in Europe at 115 µg/day of its main constituent, forbidden in Canadian food, and sold in the US as a supplement with no declaration of the one property that determines which regime should apply.

Key Safety Points

• Never take calamus essential oil internally, at any dose.
• Avoid entirely in pregnancy, lactation and childhood. Giving vasambu to infants is documented as harmful in the pediatric literature.
• Assume Indian-origin material is tetraploid at 4.4 to 8.3 percent beta-asarone, and European material triploid at about 0.3 percent, unless a certificate of analysis says otherwise.
• Keep any use of triploid or tetraploid material under 2 weeks.
• Prolonged vomiting up to 15 hours and tachycardia are the documented acute overdose signs.
• The rhizome oil is a GHS Category 1B skin sensitizer, so repeated topical use carries sensitization risk.

Special Note

The 1968 FDA order and the 2005 EMA statement reached opposite conclusions from the same toxicology. FDA banned the plant; EMA set a ceiling and told manufacturers to prefer the diploid. Both are defensible. The US retail middle ground is not, because the plant sells freely, the ceiling goes unenforced, and the cytotype is never stated, so the buyer inherits a decision the regulators declined to leave to anyone.